BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25803816)

  • 1. Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication.
    Kim MH; Lee S; Koo JS; Jung KH; Park IH; Jeong J; Kim SI; Park S; Park HS; Park BW; Kim JH; Sohn J
    PLoS One; 2015; 10(3):e0120320. PubMed ID: 25803816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.
    Jia SW; Fu S; Wang F; Shao Q; Huang HB; Shao JY
    World J Gastroenterol; 2014 Jan; 20(1):183-92. PubMed ID: 24415871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.
    Peretti U; Ferrara R; Pilotto S; Kinspergher S; Caccese M; Santo A; Brunelli M; CaliĆ² A; Carbognin L; Sperduti I; Garassino M; Chilosi M; Scarpa A; Tortora G; Bria E
    Respir Res; 2016 Aug; 17(1):105. PubMed ID: 27561692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
    Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
    Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copy number gain in recurrent anaplastic lymphoma kinase (ALK) rearrangement-lung adenocarcinoma in the pleural effusion.
    Abe H; Kawahara A; Azuma K; Murakami Y; Takase Y; Naito Y; Akiba J
    Diagn Cytopathol; 2018 Sep; 46(9):744-747. PubMed ID: 29637735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC.
    Zito Marino F; Botti G; Aquino G; Ferrero S; Gaudioso G; Palleschi A; Rocco D; Salvi R; Micheli MC; Micheli P; Morabito A; Rocco G; Giordano A; De Cecio R; Franco R
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664698
    [No Abstract]   [Full Text] [Related]  

  • 7. Circulating Tumor Cells with Aberrant
    Pailler E; Oulhen M; Borget I; Remon J; Ross K; Auger N; Billiot F; Ngo Camus M; Commo F; Lindsay CR; Planchard D; Soria JC; Besse B; Farace F
    Cancer Res; 2017 May; 77(9):2222-2230. PubMed ID: 28461563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK gene amplification is associated with poor prognosis in colorectal carcinoma.
    Bavi P; Jehan Z; Bu R; Prabhakaran S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Al-Halouly T; Sairafi R; Uddin S; Al-Kuraya KS
    Br J Cancer; 2013 Nov; 109(10):2735-43. PubMed ID: 24129244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.
    Jin Y; Sun PL; Kim H; Seo AN; Jheon S; Lee CT; Chung JH
    Ann Surg Oncol; 2014 Feb; 21(2):621-8. PubMed ID: 24212721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
    Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
    J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients.
    Sukov WR; Hodge JC; Lohse CM; Akre MK; Leibovich BC; Thompson RH; Cheville JC
    Mod Pathol; 2012 Nov; 25(11):1516-25. PubMed ID: 22743654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK alteration is a frequent event in aggressive breast cancers.
    Siraj AK; Beg S; Jehan Z; Prabhakaran S; Ahmed M; R Hussain A; Al-Dayel F; Tulbah A; Ajarim D; Al-Kuraya KS
    Breast Cancer Res; 2015 Sep; 17():127. PubMed ID: 26384210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic lymphoma kinase status in rhabdomyosarcomas.
    Yoshida A; Shibata T; Wakai S; Ushiku T; Tsuta K; Fukayama M; Makimoto A; Furuta K; Tsuda H
    Mod Pathol; 2013 Jun; 26(6):772-81. PubMed ID: 23307059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory breast cancer (IBC): clues for targeted therapies.
    Fernandez SV; Robertson FM; Pei J; Aburto-Chumpitaz L; Mu Z; Chu K; Alpaugh RK; Huang Y; Cao Y; Ye Z; Cai KQ; Boley KM; Klein-Szanto AJ; Devarajan K; Addya S; Cristofanilli M
    Breast Cancer Res Treat; 2013 Jul; 140(1):23-33. PubMed ID: 23784380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
    Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
    Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of anaplastic lymphoma kinase in inflammatory breast cancer.
    Robertson FM; Petricoin Iii EF; Van Laere SJ; Bertucci F; Chu K; Fernandez SV; Mu Z; Alpaugh K; Pei J; Circo R; Wulfkuhle J; Ye Z; Boley KM; Liu H; Moraes R; Zhang X; Demaria R; Barsky SH; Sun G; Cristofanilli M
    Springerplus; 2013; 2():497. PubMed ID: 24102046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
    Kim EK; Kim S
    Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.
    Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA
    J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.